A

Aclaris Therapeutics
D

ACRS

1.26500
USD
0.00
(0.00%)
مغلق
حجم التداول
19,064
الربح لكل سهم
-1
العائد الربحي
-
P/E
-1
حجم السوق
136,975,767
أصول ذات صلة
A
ADAP
0.00290
(1.05%)
0.27970 USD
A
AGIO
0.260
(0.88%)
29.850 USD
A
ALLO
-0.05500
(-5.02%)
1.04000 USD
ALNY
ALNY
0.47
(0.16%)
289.82 USD
AMGN
AMGN
-0.04
(-0.01%)
271.89 USD
A
AMRN
0.220
(2.00%)
11.220 USD
A
ARWR
-0.250
(-1.62%)
15.140 USD
A
ASND
2.290
(1.43%)
162.080 USD
B
BEAM
-0.420
(-2.43%)
16.830 USD
B
BLUE
0.00500
(0.10%)
4.99000 USD
BMRN
BMRN
-0.490
(-0.85%)
57.500 USD
C
CAPR
-0.615
(-5.66%)
10.245 USD
C
CRSP
-0.760
(-2.02%)
36.850 USD
E
EDIT
-0.07000
(-4.32%)
1.55000 USD
المزيد
الأخبار المقالات

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.